What are the latest funding news in the biotechnology market? (October 2026)
Building a startup or looking for your next investment in biotechnology? Our report gives you the full picture.
Private biotechnology fundraising remained heavily concentrated in therapeutics at the start of October 2026, although diagnostics and life-science research tools also appeared among the latest deals.
The 12 financing events below represent about $399M of newly disclosed capital when financing extensions are counted at the incremental amount announced.
Large biotechnology rounds were concentrated around clinical-stage drug developers, while smaller financings backed specialized diagnostics, bioanalytics and early oncology programs.
And if you want to better understand this new industry, you can download our pitch covering the biotechnology market.
Insights
- Therapeutics accounted for 10 of the 12 latest biotechnology funding deals, or about 83%, showing how strongly private biotech capital remains focused on companies developing new medicines.
- Six companies raised at least $30M of new capital, and those deals represented roughly $367M, or more than 90% of the capital captured in this biotechnology funding sample.
- The six smallest deals were all below $10M and together represented only about $32M, highlighting the large funding gap between early biotechnology programs and capital-intensive clinical development.
- Eight of the 12 biotechnology deals were announced on September 29 or September 30, making those two days unusually active for private biotech financing.
- Seven of the 12 companies were already in clinical development or preparing for a near-term clinical study, reinforcing investor preference for biotechnology programs with visible human-development milestones.
- U.S.-based biotechnology companies represented six of the 12 deals, while five came from Europe and one from India, showing that the latest private funding activity remained geographically broad.
- Advanced therapeutic modalities were prominent across the cohort, including ADCs, RNA therapeutics, mRNA delivery, engineered proteins and logic-gated CAR-T cell therapies.
- Biotia and Aventix were the two clear non-therapeutic exceptions, showing continued biotechnology investment in molecular diagnostics and research tools that generate actionable biological data.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
In our report covering the biotech market, you will always find fresh funding data, taken straight from our own verified funding database.
Summary table of the latest funding deals in the biotechnology market as of October 2026
We define the biotechnology market as products and services that apply modern biological science and engineering to create or improve medical and life-science outcomes.
We include biopharma R&D and therapeutics, including biologics, cell and gene therapies, and vaccines, molecular diagnostics, and core life-science research tools and reagents used to generate and analyze biological data.
We exclude routine healthcare delivery, conventional pharmaceuticals and chemicals not enabled by biotechnology, and agriculture or industrial bioapplications unless they are explicitly in scope for the analysis.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| ZoeNCure Therapeutics | October 3, 2026 | $2.4M | Seed | Oncology therapeutics, ADCs & cell therapy |
| TriGemX Bio | October 1, 2026 | $94M | Private financing | Neurology & migraine therapeutics |
| Biotia | October 1, 2026 | $9M | Follow-on financing | Molecular diagnostics & clinical metagenomics |
| AnaCardio | September 30, 2026 | ~$72M | Series B | Cardiovascular therapeutics |
| R1 Therapeutics | September 30, 2026 | $3M extension | Series A extension | Nephrology therapeutics |
| Astrocyte Pharmaceuticals | September 30, 2026 | $9.5M | Series B | Neuroscience & neuroprotection therapeutics |
| Aventix | September 30, 2026 | ~$1.4M | Pre-seed | Bioanalytics & life-science research tools |
| Aptadir Therapeutics | September 29, 2026 | ~$45M | Seed | RNA therapeutics & epigenetic medicines |
| ai3Bio | September 29, 2026 | $48M | Series A | Autoimmune therapeutics, mRNA & biologics |
| Breye Therapeutics | September 29, 2026 | ~$78M | Series A | Ophthalmology therapeutics |
| Peptomyc | September 29, 2026 | ~$6.7M total | Equity financing | Oncology protein therapeutics |
| Link Cell Therapies | September 28, 2026 | $30M extension | Series A extension | Oncology & CAR-T cell therapy |
All the latest funding deals in the biotechnology market as of October 2026
ZoeNCure Therapeutics raised $2.4M in early October 2026.
When was it?
ZoeNCure Therapeutics announced the seed financing on October 3, 2026.
Who are they?
ZoeNCure Therapeutics is an Indian oncology biotech developing antibody-drug conjugates and cell therapies for difficult liver and gastrointestinal cancers.
Geographical focus?
ZoeNCure Therapeutics is headquartered in India and is initially building its clinical development program around the Indian market, with potential for broader global development.
Why do we include them in the biotechnology market?
ZoeNCure Therapeutics belongs in biotechnology because its core products are engineered cancer medicines, placing it in oncology therapeutics, ADCs and cell therapy.
What is the company stage?
ZoeNCure Therapeutics is at the preclinical and IND-enabling stage and is preparing its lead ADC for first-in-human testing.
How much did they raise?
ZoeNCure Therapeutics raised about $2.4M, equivalent to ₹20 crore.
What round is it?
ZoeNCure Therapeutics described the financing as a seed round.
Why did they raise?
ZoeNCure Therapeutics raised the capital to fund preclinical studies, manufacturing work and regulatory submissions needed to move its lead ADC toward Phase 1.
In our research about biotech companies, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
TriGemX Bio raised $94M in October 2026 to advance its migraine program.
When was it?
TriGemX Bio announced the financing on October 1, 2026.
Who are they?
TriGemX Bio, formerly Kallyope, develops elismetrep, an oral TRPM8 channel blocker being tested as an acute treatment for migraine.
Geographical focus?
TriGemX Bio is based in New York and is developing its therapeutic pipeline for a broader international market.
Why do we include them in the biotechnology market?
TriGemX Bio belongs in biotechnology because the company develops novel human medicines based on neuroscience biology, within neurology and clinical-stage therapeutics.
What is the company stage?
TriGemX Bio is a late clinical-stage biotechnology company with elismetrep already in Phase 3 development.
How much did they raise?
TriGemX Bio raised $94M in the newly announced financing.
What round is it?
TriGemX Bio announced the transaction as a private financing without a conventional Series label.
Why did they raise?
TriGemX Bio raised the capital primarily to finance Phase 3 development of elismetrep and support the company's new strategic focus.
Biotia raised $9M in October 2026 to scale its infectious disease diagnostics.
When was it?
Biotia announced the financing on October 1, 2026.
Who are they?
Biotia uses clinical metagenomic sequencing and artificial intelligence to identify pathogens and antimicrobial-resistance signals in complex infections.
Geographical focus?
Biotia is based in New York and primarily serves the U.S. clinical diagnostics market while also supporting international genomic research users.
Why do we include them in the biotechnology market?
Biotia belongs in biotechnology because it analyzes biological samples through genomic sequencing for clinical diagnosis, placing it in molecular diagnostics and clinical metagenomics.
What is the company stage?
Biotia has reached commercial and growth stage, with diagnostic products already available and additional assays being introduced.
How much did they raise?
Biotia raised $9M in the financing.
What round is it?
Biotia described the deal as a new follow-on financing rather than assigning a new formal Series label.
Why did they raise?
Biotia raised the money to expand its laboratory, introduce more women's-health tests, enter orthopedic diagnostics and strengthen commercialization.
AnaCardio raised about $72M in a Series B in late September 2026.
When was it?
AnaCardio announced the Series B financing on September 30, 2026.
Who are they?
AnaCardio develops AC01, an oral therapy designed to improve cardiac contractility in patients with advanced heart failure.
Geographical focus?
AnaCardio is a Swedish biotechnology company developing AC01 for patients in major markets including Europe and North America.
Why do we include them in the biotechnology market?
AnaCardio belongs in biotechnology because its business centers on biology-driven drug development, within cardiovascular therapeutics.
What is the company stage?
AnaCardio has achieved clinical proof of concept and is moving AC01 into a Phase 2b program.
How much did they raise?
AnaCardio raised €62.5M, equivalent to roughly $72M around the announcement date.
What round is it?
AnaCardio raised a Series B financing.
Why did they raise?
AnaCardio raised the capital to fully fund the GOAL-HF2 Phase 2b study and generate the evidence required to prepare AC01 for Phase 3.
In our market report about biotech companies, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
R1 Therapeutics added $3M to its Series A in late September 2026.
When was it?
R1 Therapeutics announced the Series A expansion on September 30, 2026.
Who are they?
R1 Therapeutics develops AP306, a pan-phosphate-transporter inhibitor designed to lower phosphate levels in dialysis patients with chronic kidney disease.
Geographical focus?
R1 Therapeutics is U.S.-based and is developing AP306 through a global clinical program.
Why do we include them in the biotechnology market?
R1 Therapeutics belongs in biotechnology because its core business is developing a novel medicine for kidney disease, within nephrology therapeutics.
What is the company stage?
R1 Therapeutics is a clinical-stage company with AP306 being evaluated in a global Phase 2b program.
How much did they raise?
R1 Therapeutics added $3M of new capital, increasing the total Series A from $77.5M to $80.5M.
What round is it?
R1 Therapeutics classified the new investment as an extension of its Series A.
Why did they raise?
R1 Therapeutics raised the additional capital to support the global Phase 2b trial of AP306 and carry the program toward its next clinical readout.
Astrocyte Pharmaceuticals raised $9.5M in a Series B in late September 2026.
When was it?
Astrocyte Pharmaceuticals announced the financing on September 30, 2026.
Who are they?
Astrocyte Pharmaceuticals develops neuroprotective therapies that use astrocyte and glial biology to protect brain tissue after concussion, traumatic brain injury and stroke.
Geographical focus?
Astrocyte Pharmaceuticals is U.S.-based and also conducts clinical development work internationally, including in Australia.
Why do we include them in the biotechnology market?
Astrocyte Pharmaceuticals belongs in biotechnology because it develops novel medicines based on brain-cell biology, within neuroscience and neuroprotection therapeutics.
What is the company stage?
Astrocyte Pharmaceuticals is in Phase 2 clinical development, with enrollment completed in its STARFAST sports-concussion study.
How much did they raise?
Astrocyte Pharmaceuticals raised $9.5M.
What round is it?
Astrocyte Pharmaceuticals raised a Series B financing.
Why did they raise?
Astrocyte Pharmaceuticals raised the capital to continue Phase 2 development of AST-004 and advance its broader brain-injury clinical program.
Aventix raised about $1.4M in a pre-seed round in late September 2026.
When was it?
Aventix announced the financing on September 30, 2026.
Who are they?
Aventix builds sensor-based laboratory instruments that produce precise and machine-readable measurements for bioanalytics, genomics, PCR and cell-based assays.
Geographical focus?
Aventix is based in Sweden and is rolling out its first product to laboratories in North America and Europe.
Why do we include them in the biotechnology market?
Aventix belongs in biotechnology because its laboratory platform generates biological research data, placing it in bioanalytics and life-science research tools.
What is the company stage?
Aventix is at an early commercial stage, with its Scarlett 01 instrument being introduced through an Early Access Program.
How much did they raise?
Aventix raised €1.2M, equivalent to roughly $1.4M.
What round is it?
Aventix raised a pre-seed financing.
Why did they raise?
Aventix raised the capital to expand the commercial rollout of Scarlett 01, grow its software and applications teams and broaden its analytical capabilities.
Our document detailing everything you need to know about biotech gets updated several times a month, so you always get the latest view of where things stand.
Aptadir Therapeutics raised about $45M in a seed round in late September 2026.
When was it?
Aptadir Therapeutics announced the financing on September 29, 2026.
Who are they?
Aptadir Therapeutics develops programmable RNA inhibitors designed to reverse abnormal DNA methylation and reactivate genes silenced in genetic disorders and cancer.
Geographical focus?
Aptadir Therapeutics is headquartered in Italy and is built around scientific work originating across Italy, the United States and Singapore.
Why do we include them in the biotechnology market?
Aptadir Therapeutics belongs in biotechnology because it engineers RNA medicines that alter gene regulation, within RNA therapeutics and epigenetic medicines.
What is the company stage?
Aptadir Therapeutics is at the preclinical and IND-enabling stage with its first programs progressing toward clinical development.
How much did they raise?
Aptadir Therapeutics raised €40M, reported as approximately $45M.
What round is it?
Aptadir Therapeutics raised a seed financing.
Why did they raise?
Aptadir Therapeutics raised the capital to advance its RNA therapeutics pipeline, including its lead Fragile X syndrome program.
ai3Bio raised $48M in a Series A in late September 2026.
When was it?
ai3Bio announced the Series A financing on September 29, 2026.
Who are they?
ai3Bio develops mRNA and antibody technologies designed to selectively eliminate disease-causing Th17 cells in autoimmune disorders.
Geographical focus?
ai3Bio is U.S.-based and is initially focused on developing therapies for autoimmune diseases.
Why do we include them in the biotechnology market?
ai3Bio belongs in biotechnology because its therapeutic platforms combine mRNA delivery, antibodies and immune-cell targeting, within autoimmune therapeutics and biologics.
What is the company stage?
ai3Bio is at the preclinical and IND-enabling stage and is preparing its platforms for first-in-human studies.
How much did they raise?
ai3Bio raised $48M.
What round is it?
ai3Bio raised a Series A financing.
Why did they raise?
ai3Bio raised the capital to complete IND-enabling work and move its Th17-targeting platforms toward human autoimmune trials.
Breye Therapeutics raised about $78M in a Series A in late September 2026.
When was it?
Breye Therapeutics announced the financing on September 29, 2026.
Who are they?
Breye Therapeutics develops oral medicines for retinal diseases, including danegaptide for non-proliferative diabetic retinopathy.
Geographical focus?
Breye Therapeutics is based in Denmark and is pursuing a global clinical-development strategy for retinal diseases.
Why do we include them in the biotechnology market?
Breye Therapeutics belongs in biotechnology because its business is focused on novel disease-modifying medicines, within ophthalmology therapeutics.
What is the company stage?
Breye Therapeutics is clinical-stage and is preparing danegaptide for a randomized Phase 2 proof-of-concept study.
How much did they raise?
Breye Therapeutics raised €67.5M, equivalent to roughly $78M around the announcement period.
What round is it?
Breye Therapeutics raised a Series A financing.
Why did they raise?
Breye Therapeutics raised the capital to move danegaptide into Phase 2 and continue developing its broader retinal-disease pipeline.
In our report covering the biotech market, we look at what the winners do differently, so you can learn from the best instead of guessing.
Peptomyc closed about $6.7M of equity financing in late September 2026.
When was it?
Peptomyc announced the final closing of the financing on September 29, 2026.
Who are they?
Peptomyc develops Omomyc-derived cell-penetrating mini-proteins that directly inhibit MYC, a major driver of cancer growth.
Geographical focus?
Peptomyc is based in Barcelona and is developing its oncology programs through an international clinical strategy.
Why do we include them in the biotechnology market?
Peptomyc belongs in biotechnology because its main products are engineered therapeutic proteins based on molecular cancer biology, within oncology and protein therapeutics.
What is the company stage?
Peptomyc is a clinical-stage biotechnology company with OMO-103 being evaluated across multiple studies, including Phase 2 work.
How much did they raise?
Peptomyc closed a €5.7M financing, equivalent to roughly $6.7M, with the September closing completing the broader round.
What round is it?
Peptomyc described the transaction as an equity financing and final close rather than assigning a formal Series label.
Why did they raise?
Peptomyc raised the capital to complete ongoing OMO-103 studies, strengthen manufacturing readiness and prepare for later-stage development and partnering.
Link Cell Therapies added $30M to its Series A in late September 2026.
When was it?
Link Cell Therapies announced the expanded financing on September 28, 2026.
Who are they?
Link Cell Therapies develops logic-gated CAR-T therapies that require two cancer-associated antigens before engineered T cells attack a tumor.
Geographical focus?
Link Cell Therapies is U.S.-based and is currently running clinical development through centers including MD Anderson Cancer Center.
Why do we include them in the biotechnology market?
Link Cell Therapies belongs in biotechnology because the company is entirely focused on engineered cell medicines, within oncology and CAR-T cell therapy.
What is the company stage?
Link Cell Therapies is at the early clinical stage and has started Phase 1 dosing with its lead program LNK001.
How much did they raise?
Link Cell Therapies added $30M of new capital, increasing its Series A from $60M to $90M in total.
What round is it?
Link Cell Therapies announced the financing as a Series A extension.
Why did they raise?
Link Cell Therapies raised the additional capital to advance a second solid-tumor CAR-T program and expand its broader logic-gated cell-therapy pipeline.
Theory only gets you so far. In our research about biotech companies, we dig up the real signals from the field and show you the ones worth watching.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us